COMPANIES UCB, the Belgian pharmaceuticals and chemicals group, gave its clearest signal yet that it was planning to split its two businesses up yesterday, as it reported a 34 per cent rise in first-half profits.
Baron Daniel Janssen, chief executive, said the company had received "a lot of interest" in its chemicals arm since the acquisition of Celltech, the UK's largest biotechnology company, for £1.53bn ($2.8bn) in May.
